These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28282366)

  • 1. Comparing Azole Plasma Trough Levels in Lung Transplant Recipients: Percentage of Therapeutic Levels and Intrapatient Variability.
    Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
    Ther Drug Monit; 2017 Apr; 39(2):93-101. PubMed ID: 28282366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posaconazole liquid vs tablet formulation in lung transplant recipients.
    Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
    Mycoses; 2018 Mar; 61(3):186-194. PubMed ID: 29110351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations.
    Gautier-Veyret E; Bolcato L; Roustit M; Weiss S; Tonini J; Brenier-Pinchart MP; Cornet M; Thiebaut-Bertrand A; Stanke-Labesque F
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations.
    Jeong W; Snell GI; Levvey BJ; Westall GP; Morrissey CO; Wolfe R; Ivulich S; Neoh CF; Slavin MA; Kong DCM
    J Antimicrob Chemother; 2018 Mar; 73(3):748-756. PubMed ID: 29211913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effectiveness of early posaconazole suspension pre-emptive therapy in lung transplant recipients: The Alfred's experience.
    Jeong W; Snell GI; Levvey BJ; Westall GP; Morrissey CO; Ivulich S; Neoh CF; Slavin MA; Kong DCM
    J Antimicrob Chemother; 2017 Jul; 72(7):2089-2092. PubMed ID: 28369489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital.
    Cabral-Galeano E; Ruiz-Camps I; Len-Abad O; Pou-Clavé L; Sordé-Masip R; Meije-Castillo Y; Blanco-Grau A; Barba-Suñol P; Monforte-Torres V; Román-Broto A; Pahissa-Berga A; Gavaldà-Santapau J
    Enferm Infecc Microbiol Clin; 2015 May; 33(5):298-302. PubMed ID: 25459191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing posaconazole and itraconazole for antifungal prophylaxis in critically ill lung transplant recipients: Efficacy and plasma concentrations.
    Kallee S; Scharf C; Schroeder I; Paal M; Vogeser M; Irlbeck M; Zander J; Zoller M; Jung J; Kneidinger N; Schneider C; Michel S; Liebchen U
    Transpl Infect Dis; 2021 Aug; 23(4):e13675. PubMed ID: 34166573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
    Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
    J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous quantification of systemic azoles and their major metabolites in human serum by HPLC/PDA: role of azole metabolic rate.
    Gomez-Lopez A; Alcazar-Fuoli L; Bernal-Martínez L
    Diagn Microbiol Infect Dis; 2018 Sep; 92(1):78-83. PubMed ID: 29778564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a liquid chromatography tandem mass spectrometry method for the simultaneous measurement of voriconazole, posaconazole and itraconazole.
    Wadsworth JM; Milan AM; Anson J; Davison AS
    Ann Clin Biochem; 2017 Nov; 54(6):686-695. PubMed ID: 27941128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for subtherapeutic levels of posaconazole tablet.
    Tang LA; Marini BL; Benitez L; Nagel JL; Miceli M; Berglund C; Perissinotti AJ
    J Antimicrob Chemother; 2017 Oct; 72(10):2902-2905. PubMed ID: 29091205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The synergistic effect of minocycline and azole antifungal drugs against Scedosporium and Lomentospora species.
    Yang F; Sun Y; Lu Q
    BMC Microbiol; 2022 Jan; 22(1):21. PubMed ID: 35016611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients.
    Billaud EM; Guillemain R; Berge M; Amrein C; Lefeuvre S; Louët AL; Boussaud V; Chevalier P
    Med Mycol; 2010 Nov; 48 Suppl 1():S52-9. PubMed ID: 21067331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness.
    Cadena J; Levine DJ; Angel LF; Maxwell PR; Brady R; Sanchez JF; Michalek JE; Levine SM; Restrepo MI
    Am J Transplant; 2009 Sep; 9(9):2085-91. PubMed ID: 19645709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.
    Neofytos D; Ostrander D; Shoham S; Laverdiere M; Hiemenz J; Nguyen H; Clarke W; Brass L; Lu N; Marr KA
    Transpl Infect Dis; 2015 Dec; 17(6):831-7. PubMed ID: 26346408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of drug and food interactions with azole antifungal agents in transplant recipients.
    Dodds-Ashley E
    Pharmacotherapy; 2010 Aug; 30(8):842-54. PubMed ID: 20653361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
    Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between drug tolerability and medical resource use in prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplant.
    Gao X; Marks DI; Schlamm HT; Ji X; Stephens JM; Tarallo M
    J Med Econ; 2013 Aug; 16(8):1061-70. PubMed ID: 23730943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations.
    Brüggemann RJ; Touw DJ; Aarnoutse RE; Verweij PE; Burger DM
    Antimicrob Agents Chemother; 2009 Jan; 53(1):303-5. PubMed ID: 19015363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why do lung transplant patients discontinue triazole prophylaxis?
    Pennington KM; Razonable RR; Peters S; Scott JP; Wylam M; Daly RC; Kennedy CC
    Transpl Infect Dis; 2019 Jun; 21(3):e13067. PubMed ID: 30866168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.